Recombinant Human Keratinocyte Growth Factor in Unrelated and Related Transplants

University of Michigan

Status and phase: Completed; Phase 2; Phase 1

Conditions: Graft Versus Host Disease

Treatments: Drug: recombinant human keratinocyte growth factor

Study type: Interventional

Funder types: Other

Identifiers

NCT00056875

2146

Details and patient eligibility

About

This is a single arm dose escalation study of recombinant human keratinocyte growth factor given to patients undergoing allogeneic bone marrow transplantation who are at high risk for graft versus host disease (GVHD).

Full description

Completion date provided represents the completion date of the grant per OOPD records

Sex: All

Ages: 3 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Eligible for full intensity bone marrow transplant (BMT) conditioning but who lack a 6/6 HLA idential sibling donor